Insulin Glargine in Continuous Enteric Tube Feeding
- Darcy Putz, MD and
- Udaya M. Kabadi, MD
- 1From the Division of Endocrinology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa
In comparison with the traditional long-acting insulins, i.e., NPH and Ultralente (1–3), insulin glargine, a novel insulin analogue has been documented to decrease the number of hypoglycemic episodes while achieving an adequate glycemic control. The decline in hypoglycemic events, especially nocturnal, is attributed to the ability of insulin glargine to attain a steady-state plasma insulin concentration without a peak for ∼24 h on a subcutaneous (SC) administration of a single dose (4). Therefore, insulin glargine may achieve an effect similar to that obtained by continuous intravenous (IV) or SC infusion of regular insulin in …
